Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
FDA Accepts Takeda’s Resubmission for Eosinophilic Esophagitis Drug
The US FDA has accepted for review a resubmission made by Takeda Pharmaceutical for its eosinophilic esophagitis (EoE) treatment TAK-721 (budesonide oral suspension), the company said on September 20. A decision from the regulator is expected in the first half…
To read the full story
Related Article
- Takeda Earns US Nod for Oral EoE Drug after Resubmission
February 14, 2024
- Takeda’s Eosinophilic Esophagitis Drug Rejected in US
December 23, 2021
- Takeda’s Eosinophilic Esophagitis Med Gets Priority Review in US
December 17, 2020
BUSINESS
- Sanofi Debuts Sarclisa SC, Cutting Dosing Time
August 28, 2026
- Daiichi Starts Global PIII of Datroway in Adjuvant Urothelial Cancer
August 28, 2026
- FDA Accepts Kowa’s Glaucoma Drug K-911 for Review
August 28, 2026
- Hokuriku Downpours Cripple Some Drug Deliveries; Wholesalers Report No Damage
August 28, 2026
- Shionogi, Susmed End Sales Partnership for Insomnia App
August 27, 2026
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…